PhaseBio Overview
- Founded
-
2002
- Status
-
Public
- Employees
-
60
- Stock Symbol
-
PHASQ
- Investments
-
2
PhaseBio General Information
Description
PhaseBio Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary indications. The lead product candidate of the company is PB2452, which is a novel reversal agent for the antiplatelet drug ticagrelor, used for the treatment of patients experiencing major bleeding or those who require urgent surgery. It is also developing PB1046 which is a fusion protein for the treatment of pulmonary arterial hypertension. The company is also developing its preclinical product candidate, PB6440, for treatment-resistant hypertension.
Contact Information
- One Great Valley Parkway
- Suite 30
- Malvern, PA 19355
- United States
PhaseBio Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| 22.5K | -$2.13 |
PhaseBio Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 17,365 | 78,942 | 74,889 | 105,537 |
| Revenue | 818 | 10,831 | 0 | 2,361 |
| EBITDA | (100,255) | (126,745) | (96,849) | (39,553) |
| Net Income | (102,840) | (131,071) | (98,565) | (39,247) |
| Total Assets | 22,166 | 60,540 | 50,357 | 82,494 |
| Total Debt | 5,372 | 8,320 | 14,066 | 16,477 |
PhaseBio Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
PhaseBio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
PhaseBio Comparisons
Industry
Financing
Details
000000
000
PhaseBio Competitors (100)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Sigilon Therapeutics | Formerly VC-backed | Cambridge, MA | 00 | 00000 | 000000&0 | 00000 |
| 000 | Corporation | Brussels, Belgium | 0000 | 00000 | 000000 - 000 | 00000 |
| 000000 00000000000 | Corporation | Cleveland, OH | 00 | 00000 | 000000000 | 00000 |
| 000000 00000000000 | Formerly VC-backed | Zug, Switzerland | 000 | 00000 | 000000000 | 00000 |
| 000000 00000000000 | Corporate Backed or Acquired | Basking Ridge, NJ | 00 | 00000 | 000000000 | 00000 |
PhaseBio Patents
PhaseBio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230173030-A1 | Vasoactive intestinal peptide fusion proteins for the treatment of covid-19 | Pending | 05-May-2020 | 00000000000 | |
| EP-4010008-A1 | Elp fusion proteins comprising parathyroid hormone for controlled and sustained release | Pending | 09-Aug-2019 | 0000000000 | |
| US-20220289812-A1 | Elp fusion proteins comprising parathyroid hormone for controlled and sustained release | Pending | 09-Aug-2019 | 0000000000 | |
| EP-4010008-A4 | Elp fusion proteins comprising parathyroid hormone for controlled and sustained release | Pending | 09-Aug-2019 | 000000000 | 0 |
| AU-2017387033-A1 | Metalloenzyme inhibitor compounds | Pending | 29-Dec-2016 | A61K31/501 |
PhaseBio Executive Team (15)
PhaseBio Board Members (22)
| Name | Representing | Role | Since |
|---|---|---|---|
| Alex Sapir | Self | Board Member | 000 0000 |
| Ashutosh Chilkoti Ph.D | Self | Co-Founder and Board Member | 000 0000 |
| Caroline Loewy | Self | Board Member | 000 0000 |
| Clay Thorp | Self | Chairman & Board Member | 000 0000 |
| Donald Dwyer | AstraZeneca | Board Observer | 000 0000 |
PhaseBio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PhaseBio Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
PhaseBio Investments (2)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000000 000000 | 13-Jan-2020 | 000000000 | 00000 | Buildings and Property | 00000000 |
| ImmunoForge | 01-Mar-2019 | Early Stage VC | 00.000 | Drug Discovery |
PhaseBio ESG
Risk Overview
Risk Rating
Updated April, 30, 2021
40.84 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 14,042
Rank
Percentile
Pharmaceuticals
Industry
00 of 947
Rank
Percentile
Pharmaceuticals
Subindustry
00 of 452
Rank
Percentile
